Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – ADROVANCE

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Vitamin D3 (kolekalciferol) Testmiljö

Vitamin D3 (kolekalciferol)

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review - FOSAMAX PLUS (alendronate and cholecalciferol). Food and Drug Administration [www]. [updated 2005-07-04, cited 2016-11-17].

  2. Holvik K, Madar AA, Meyer HE, Lofthus CM, Stene LC. A randomised comparison of increase in serum 25-hydroxyvitamin D concentration after 4 weeks of daily oral intake of 10 microg cholecalciferol from multivitamin tablets or fish oil capsules in healthy young adults. Br J Nutr. 2007;98:620-5.

  3. Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot Ld et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ. 2014;348:g3656.

  4. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, Yetley EA, Looker AC, Schleicher RL et al. Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the US nationally representative NHANES. J Clin Endocrinol Metab. 2013;98:3001-9.

  5. Granic A, Aspray T, Hill T, Davies K, Collerton J, Martin-Ruiz C et al. 25-hydroxyvitamin D and increased all-cause mortality in very old women: the Newcastle 85+ study. J Intern Med. 2015;277:456-67.

  6. Sun Q, Shi L, Rimm EB, Giovannucci EL, Hu FB, Manson JE et al. Vitamin D intake and risk of cardiovascular disease in US men and women. Am J Clin Nutr. 2011;94:534-42.

  7. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. 2000;15:1113-8.

  8. Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. J Am Geriatr Soc. 2003;51:1219-26.

  9. Andersen R, Mølgaard C, Skovgaard LT, Brot C, Cashman KD, Jakobsen J et al. Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention study. Br J Nutr. 2008;100:197-207.

  10. Wu F, Laslett LL, Zhang Q. Threshold Effects of Vitamin D Status on Bone Health in Chinese Adolescents With Low Calcium Intake. J Clin Endocrinol Metab. 2015;100:4481-9.

  11. Dennis NA, Houghton LA, Jones GT, van Rij AM, Morgan K, McLennan IS. The level of serum anti-Müllerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab. 2012;97:2450-5.

  12. Hagenau T, Vest R, Gissel TN, Poulsen CS, Erlandsen M, Mosekilde L et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int. 2009;20:133-40.

  13. Damsgaard CT, Dalskov SM, Petersen RA, Sørensen LB, Mølgaard C, Biltoft-Jensen A et al. Design of the OPUS School Meal Study: a randomised controlled trial assessing the impact of serving school meals based on the New Nordic Diet. Scand J Public Health. 2012;40:693-703.

  14. Petersen RA, Damsgaard CT, Dalskov SM, Sørensen LB, Hjorth MF, Ritz C et al. Vitamin D status and its determinants during autumn in children at northern latitudes: a cross-sectional analysis from the optimal well-being, development and health for Danish children through a healthy New Nordic Diet (OPUS) School Meal Study. Br J Nutr. 2016;115:239-50.

  15. Houghton LA, Gray AR, Harper MJ, Winichagoon P, Pongcharoen T, Gowachirapant S et al. Vitamin D status among Thai school children and the association with 1,25-Dihydroxyvitamin D and parathyroid hormone levels. PLoS One. 2014;9:e104825.

  16. Pieper CF, Colon-Emeric C, Caminis J, Betchyk K, Zhang J, Janning C et al. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother. 2007;5:335-40.

  17. Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum. 2002;47:651-4.

  18. Indridason OS, Pieper CF, Quarles LD. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. J Clin Endocrinol Metab. 1998;83:3860-6.

  19. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11:315-21.

  20. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-11-08.]

  1. Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review - FOSAMAX PLUS (alendronate and cholecalciferol). Food and Drug Administration [www]. [updated 2005-07-04, cited 2016-11-17].
  2. Holvik K, Madar AA, Meyer HE, Lofthus CM, Stene LC. A randomised comparison of increase in serum 25-hydroxyvitamin D concentration after 4 weeks of daily oral intake of 10 microg cholecalciferol from multivitamin tablets or fish oil capsules in healthy young adults. Br J Nutr. 2007;98:620-5.
  3. Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot Ld et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ. 2014;348:g3656.
  4. Sempos CT, Durazo-Arvizu RA, Dawson-Hughes B, Yetley EA, Looker AC, Schleicher RL et al. Is there a reverse J-shaped association between 25-hydroxyvitamin D and all-cause mortality? Results from the US nationally representative NHANES. J Clin Endocrinol Metab. 2013;98:3001-9.
  5. Granic A, Aspray T, Hill T, Davies K, Collerton J, Martin-Ruiz C et al. 25-hydroxyvitamin D and increased all-cause mortality in very old women: the Newcastle 85+ study. J Intern Med. 2015;277:456-67.
  6. Sun Q, Shi L, Rimm EB, Giovannucci EL, Hu FB, Manson JE et al. Vitamin D intake and risk of cardiovascular disease in US men and women. Am J Clin Nutr. 2011;94:534-42.
  7. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. 2000;15:1113-8.
  8. Latham NK, Anderson CS, Reid IR. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. J Am Geriatr Soc. 2003;51:1219-26.
  9. Andersen R, Mølgaard C, Skovgaard LT, Brot C, Cashman KD, Jakobsen J et al. Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention study. Br J Nutr. 2008;100:197-207.
  10. Wu F, Laslett LL, Zhang Q. Threshold Effects of Vitamin D Status on Bone Health in Chinese Adolescents With Low Calcium Intake. J Clin Endocrinol Metab. 2015;100:4481-9.
  11. Dennis NA, Houghton LA, Jones GT, van Rij AM, Morgan K, McLennan IS. The level of serum anti-Müllerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab. 2012;97:2450-5.
  12. Hagenau T, Vest R, Gissel TN, Poulsen CS, Erlandsen M, Mosekilde L et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int. 2009;20:133-40.
  13. Damsgaard CT, Dalskov SM, Petersen RA, Sørensen LB, Mølgaard C, Biltoft-Jensen A et al. Design of the OPUS School Meal Study: a randomised controlled trial assessing the impact of serving school meals based on the New Nordic Diet. Scand J Public Health. 2012;40:693-703.
  14. Petersen RA, Damsgaard CT, Dalskov SM, Sørensen LB, Hjorth MF, Ritz C et al. Vitamin D status and its determinants during autumn in children at northern latitudes: a cross-sectional analysis from the optimal well-being, development and health for Danish children through a healthy New Nordic Diet (OPUS) School Meal Study. Br J Nutr. 2016;115:239-50.
  15. Houghton LA, Gray AR, Harper MJ, Winichagoon P, Pongcharoen T, Gowachirapant S et al. Vitamin D status among Thai school children and the association with 1,25-Dihydroxyvitamin D and parathyroid hormone levels. PLoS One. 2014;9:e104825.
  16. Pieper CF, Colon-Emeric C, Caminis J, Betchyk K, Zhang J, Janning C et al. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother. 2007;5:335-40.
  17. Harrington JT, Broy SB, Derosa AM, Licata AA, Shewmon DA. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum. 2002;47:651-4.
  18. Indridason OS, Pieper CF, Quarles LD. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: role of phosphorus, calcium, and gender. J Clin Endocrinol Metab. 1998;83:3860-6.
  19. Del Valle E, Negri AL, Aguirre C, Fradinger E, Zanchetta JR. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int. 2007;11:315-21.
  20. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-11-08.]
A A
A A

Alendronat Testmiljö

Alendronat

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Läkemedelsverket. Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation. Läkemedelsverket [www]. [updated 2020-04-30, cited 2020-06-11].

  2. Kaufman JM, Lapauw B, Goemaere S. Current and future treatments of osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2014;28(6):871-84.

  3. Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2018;32(5):759-772.

  4. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58:288-98.

  5. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339:292-9.

  6. Bonnick SL. Osteoporosis in men and women. Clin Cornerstone. 2006;8:28-39.

  7. Ho YV, Frauman AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int. 2000;11:98-101.

  8. Iwamoto J, Takeda T, Sato Y, Uzawa M. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol. 2007;26:161-7.

  9. Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005;6:39.

  10. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V et al. Meta-analyses of therapies for postmenopausal osteoporosis II Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-16.

  11. Ringe JD, Orwoll E, Daifotis A, Lombardi A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int. 2002;13:195-9.

  12. Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21:297-304.

  13. Martín-Merino E, Huerta-Álvarez C, Prieto-Alhambra D, Montero-Corominas D. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos. 2017;12(1):39.

  14. Bor A, Matuz M, Gyimesi N, Biczók Z, Soós G, Doró P. Gender inequalities in the treatment of osteoporosis. Maturitas. 2015;80(2):162-9.

  15. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  16. Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8:137.

  17. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.

  18. Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxillofac Surg. 2017;45(9):1493-1502.

  19. Khominsky A, Lim M. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review. Aust Dent J. 2018;63(4):441-454.

  20. Ulmner M, Jarnbring F, Törring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg. 2014;72(1):76-82.

  21. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100-7.

  22. McConeghy KW, Soriano MM, Danziger LH. A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile. Pharmacotherapy. 2016;36(10):1095-1101.

  23. Coloma PM, de Ridder M, Bezemer I, Herings RM, Gini R, Pecchioli S et al. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Osteoporos Int. 2016;27(5):1857-67.

  1. Läkemedelsverket. Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation. Läkemedelsverket [www]. [updated 2020-04-30, cited 2020-06-11].
  2. Kaufman JM, Lapauw B, Goemaere S. Current and future treatments of osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2014;28(6):871-84.
  3. Adler RA. Update on osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2018;32(5):759-772.
  4. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995;58:288-98.
  5. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339:292-9.
  6. Bonnick SL. Osteoporosis in men and women. Clin Cornerstone. 2006;8:28-39.
  7. Ho YV, Frauman AG, Thomson W, Seeman E. Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int. 2000;11:98-101.
  8. Iwamoto J, Takeda T, Sato Y, Uzawa M. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis. Clin Rheumatol. 2007;26:161-7.
  9. Sawka AM, Papaioannou A, Adachi JD, Gafni A, Hanley DA, Thabane L. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005;6:39.
  10. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V et al. Meta-analyses of therapies for postmenopausal osteoporosis II Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev. 2002;23:508-16.
  11. Ringe JD, Orwoll E, Daifotis A, Lombardi A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int. 2002;13:195-9.
  12. Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21:297-304.
  13. Martín-Merino E, Huerta-Álvarez C, Prieto-Alhambra D, Montero-Corominas D. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis. Arch Osteoporos. 2017;12(1):39.
  14. Bor A, Matuz M, Gyimesi N, Biczók Z, Soós G, Doró P. Gender inequalities in the treatment of osteoporosis. Maturitas. 2015;80(2):162-9.
  15. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
  16. Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8:137.
  17. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.
  18. Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxillofac Surg. 2017;45(9):1493-1502.
  19. Khominsky A, Lim M. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review. Aust Dent J. 2018;63(4):441-454.
  20. Ulmner M, Jarnbring F, Törring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg. 2014;72(1):76-82.
  21. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100-7.
  22. McConeghy KW, Soriano MM, Danziger LH. A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile. Pharmacotherapy. 2016;36(10):1095-1101.
  23. Coloma PM, de Ridder M, Bezemer I, Herings RM, Gini R, Pecchioli S et al. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Osteoporos Int. 2016;27(5):1857-67.